These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 34804937)

  • 1. A Multi-Center, Real-World Study of Chidamide for Patients With Relapsed or Refractory Peripheral T-Cell Lymphomas in China.
    Liu W; Zhao D; Liu T; Niu T; Song Y; Xu W; Jin J; Cai Q; Huang H; Li Z; Hou M; Zhang H; Zhou J; Hu J; Shen J; Shi Y; Yang Y; Zhang L; Zhao W; Ding K; Qiu L; Tan H; Zhang Z; Liu L; Wang J; Xu B; Zhou H; Gao G; Xue H; Bai O; Feng R; Huang X; Yang H; Yan X; Zeng Q; Liu P; Li W; Mao M; Su H; Wang X; Xu J; Zhou D; Zhang H; Ma J; Shen Z; Zhu J
    Front Oncol; 2021; 11():750323. PubMed ID: 34804937
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chidamide in relapsed or refractory peripheral T cell lymphoma: a multicenter real-world study in China.
    Shi Y; Jia B; Xu W; Li W; Liu T; Liu P; Zhao W; Zhang H; Sun X; Yang H; Zhang X; Jin J; Jin Z; Li Z; Qiu L; Dong M; Huang X; Luo Y; Wang X; Wang X; Wu J; Xu J; Yi P; Zhou J; He H; Liu L; Shen J; Tang X; Wang J; Yang J; Zeng Q; Zhang Z; Cai Z; Chen X; Ding K; Hou M; Huang H; Li X; Liang R; Liu Q; Song Y; Su H; Gao Y; Liu L; Luo J; Su L; Sun Z; Tan H; Wang H; Wang J; Wang S; Zhang H; Zhang X; Zhou D; Bai O; Wu G; Zhang L; Zhang Y
    J Hematol Oncol; 2017 Mar; 10(1):69. PubMed ID: 28298231
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Results from a multicenter, open-label, pivotal phase II study of chidamide in relapsed or refractory peripheral T-cell lymphoma.
    Shi Y; Dong M; Hong X; Zhang W; Feng J; Zhu J; Yu L; Ke X; Huang H; Shen Z; Fan Y; Li W; Zhao X; Qi J; Huang H; Zhou D; Ning Z; Lu X
    Ann Oncol; 2015 Aug; 26(8):1766-71. PubMed ID: 26105599
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chidamide with PEL regimen (prednisone, etoposide, lenalidomide) for elderly or frail patients with relapsed/refractory diffuse large B-Cell lymphoma -results of a single center, retrospective cohort in China.
    Wang Y; Xue H; Song W; Xiao S; Jing F; Dong T; Wang L
    Hematol Oncol; 2022 Oct; 40(4):617-625. PubMed ID: 35165928
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chidamide Maintenance Therapy Following Induction Therapy in Patients With Peripheral T-Cell Lymphoma Who Are Ineligible for Autologous Stem Cell Transplantation: Case Series From China.
    Guo W; Wang X; Li J; Yin X; Zhao Y; Tang Y; Wang A; Bai O
    Front Oncol; 2022; 12():875469. PubMed ID: 35747802
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of histone deacetylase inhibitors in peripheral T-cell lymphoma: a systematic review and meta-analysis on prospective clinical trials.
    Yang P; Tao Y; Zhao A; Shen K; Li H; Wang J; Zhou H; Wang Z; Wang M; Qu Y; Zhang L; Zheng Y; Niu T
    Front Oncol; 2023; 13():1127112. PubMed ID: 37384289
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of Chemotherapy Combined With Chidamide Versus Chemotherapy in the Frontline Treatment for Peripheral T-Cell Lymphoma.
    Wang J; Su N; Fang Y; Ma S; Zhang Y; Cai J; Zou Q; Tian X; Xia Y; Liu P; Li Z; Huang H; Huang H; Cai Q
    Front Immunol; 2022; 13():835103. PubMed ID: 35185926
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Chidamide in combination with chemotherapy in refractory and relapsed T lymphoblastic lymphoma/leukemia.
    Guan W; Jing Y; Dou L; Wang M; Xiao Y; Yu L
    Leuk Lymphoma; 2020 Apr; 61(4):855-861. PubMed ID: 31755348
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of chidamide-contained treatment modalities versus chemotherapy in the second-line treatment for relapsed or refractory peripheral T-cell lymphoma.
    Wang J; Fang Y; Ma S; Su N; Zhang Y; Huang H; Li Z; Huang H; Tian X; Cai J; Xia Y; Liu P; Cai Q
    Leuk Res; 2021 Dec; 111():106705. PubMed ID: 34534908
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chidamide combined with cyclophosphamide, doxorubicin, vincristine and prednisone in previously untreated patients with peripheral T-cell lymphoma.
    Gui L; Cao J; Ji D; Zhang H; Fan Q; Zhu J; Song Y; Jiang S; Ning Z; Yu J; Shi Y
    Chin J Cancer Res; 2021 Oct; 33(5):616-626. PubMed ID: 34815635
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Romidepsin treatment for relapsed or refractory peripheral and cutaneous T-cell lymphoma: Real-life data from a national multicenter observational study.
    Shimony S; Horowitz N; Ribakovsky E; Rozovski U; Avigdor A; Zloto K; Berger T; Avivi I; Perry C; Abadi U; Raanani P; Gafter-Gvili A; Gurion R
    Hematol Oncol; 2019 Dec; 37(5):569-577. PubMed ID: 31674027
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chidamide in the treatment of peripheral T-cell lymphoma.
    Chan TS; Tse E; Kwong YL
    Onco Targets Ther; 2017; 10():347-352. PubMed ID: 28138258
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Oral HDAC inhibitor tucidinostat in patients with relapsed or refractory peripheral T-cell lymphoma: phase IIb results.
    Rai S; Kim WS; Ando K; Choi I; Izutsu K; Tsukamoto N; Yokoyama M; Tsukasaki K; Kuroda J; Ando J; Hidaka M; Koh Y; Shibayama H; Uchida T; Yang DH; Ishitsuka K; Ishizawa K; Kim JS; Lee HG; Minami H; Eom HS; Kurosawa M; Lee JH; Lee JS; Lee WS; Nagai H; Shindo T; Yoon DH; Yoshida S; Gillings M; Onogi H; Tobinai K
    Haematologica; 2023 Mar; 108(3):811-821. PubMed ID: 36200417
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chidamide tablets: HDAC inhibition to treat lymphoma.
    Xu Y; Zhang P; Liu Y
    Drugs Today (Barc); 2017 Mar; 53(3):167-176. PubMed ID: 28447074
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effective Treatment with PD-1 Antibody, Chidamide, Etoposide, and Thalidomide (PCET) for Relapsed/Refractory Natural Killer/T-Cell Lymphoma: A Report of Three Cases.
    Du L; Zhang L; Li L; Li X; Yan J; Wang X; Fu X; Sun Z; Zhang X; Li Z; Wu J; Yu H; Chang Y; Zhou Z; Nan F; Wu X; Tian L; Zhang M
    Onco Targets Ther; 2020; 13():7189-7197. PubMed ID: 32801749
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Development of chidamide for peripheral T-cell lymphoma, the first orphan drug approved in China.
    Lu X; Ning Z; Li Z; Cao H; Wang X
    Intractable Rare Dis Res; 2016 Aug; 5(3):185-91. PubMed ID: 27672541
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gemcitabine, oxaliplatin and dexamethasone (GemDOx) as salvage therapy for relapsed or refractory diffuse large B-cell lymphoma and peripheral T-cell lymphoma.
    Shen QD; Wang L; Zhu HY; Liang JH; Xia Y; Wu JZ; Fan L; Li JY; Xu W
    J Cancer; 2021; 12(1):163-169. PubMed ID: 33391412
    [No Abstract]   [Full Text] [Related]  

  • 18. Chidamide, decitabine, cytarabine, aclarubicin, and granulocyte colony-stimulating factor (CDCAG) in patients with relapsed/refractory acute myeloid leukemia: a single-arm, phase 1/2 study.
    Wang L; Luo J; Chen G; Fang M; Wei X; Li Y; Liu Z; Zhang Y; Gao S; Shen J; Wang X; Gao X; Zhou W; Ma Y; Liu H; Li X; Yang L; Sun K; Yu L
    Clin Epigenetics; 2020 Sep; 12(1):132. PubMed ID: 32873343
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CREBBP cooperates with the cell cycle machinery to attenuate chidamide sensitivity in relapsed/refractory diffuse large B-cell lymphoma.
    Sun Y; Gao Y; Chen J; Huang L; Deng P; Chen J; Chai KXY; Hong JH; Chan JY; He H; Wang Y; Cheah D; Lim JQ; Chia BKH; Huang D; Liu L; Liu S; Wang X; Teng Y; Pang D; Grigoropoulos NF; Teh BT; Yu Q; Lim ST; Li W; Ong CK; Huang H; Tan J
    Cancer Lett; 2021 Sep; 521():268-280. PubMed ID: 34481935
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and Treatment-Related Adverse Events of Romidepsin in PTCL Clinical Studies: A Systematic Review and Meta-Analysis.
    Du J; Han X; Lin S; Qiu C; Zhu L; Huang Z; Hou J
    Front Med (Lausanne); 2021; 8():732727. PubMed ID: 34805202
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.